A Randomized First-in-Human Study With UB-312, a UBITh® &#945;-Synuclein Peptide Vaccine.

Yu, Hui Jing; Thijssen, Eva; van Brummelen, Emilie; van der Plas, Johan L; Radanovic, Igor; Moerland, Matthijs; Hsieh, Eric; Groeneveld, Geert Jan; Dodart, Jean-Cosme

A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.

Yu, Hui Jing; Thijssen, Eva; van Brummelen, Emilie; van der Plas, Johan L; Radanovic, Igor; Moerland, Matthijs; Hsieh, Eric; Groeneveld, Geert Jan; Dodart, Jean-Cosme.

Afiliação

Yu HJ; Vaxxinity Inc., Dallas, Texas, USA.
Thijssen E; Centre for Human Drug Research, Leiden, the Netherlands.
van Brummelen E; Leiden University Medical Centre, Leiden, the Netherlands.
van der Plas JL; Centre for Human Drug Research, Leiden, the Netherlands.
Radanovic I; Centre for Human Drug Research, Leiden, the Netherlands.
Moerland M; Leiden University Medical Centre, Leiden, the Netherlands.
Hsieh E; Centre for Human Drug Research, Leiden, the Netherlands.
Groeneveld GJ; Centre for Human Drug Research, Leiden, the Netherlands.
Dodart JC; Vaxxinity Inc., Dallas, Texas, USA.

Mov Disord ; 37(7): 1416-1424, 2022 07.

Article em En | MEDLINE | ID: mdl-35426173

Assuntos

Doença de Parkinson; alfa-Sinucleína; Método Duplo-Cego; Humanos; Dor; Doença de Parkinson/tratamento farmacológico; Peptídeos; Vacinas de Subunidades Antigênicas/uso terapêutico

Palavras-chave

Parkinson's disease; active immunotherapy; first-in-human; vaccine; α-synuclein

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Alfa-Sinucleína Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Mov Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google